The firm said it can detect circulating tumor DNA with a mutational allele frequency of 0.001 percent, enabled by digital PCR and the firm's proprietary chemistry.
The firm is in the midst of a clinical trial called NOVA to compare its circulating-tumor DNA-based Colvera test to DiaSorin's carcinoembryonic antigen assay.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
The University of Michigan researchers aim to commercialize the Hydro-Seq microfluidic platform, which isolates and prepares single circulating tumor cells for RNA sequencing.
The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.
The firm's "TuMatch" assay integrates patient whole-exome sequencing data and fruit fly models to develop a personalized drug therapy service for cancer patients.
A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.
